JP2022538894A5 - - Google Patents
Info
- Publication number
- JP2022538894A5 JP2022538894A5 JP2021578065A JP2021578065A JP2022538894A5 JP 2022538894 A5 JP2022538894 A5 JP 2022538894A5 JP 2021578065 A JP2021578065 A JP 2021578065A JP 2021578065 A JP2021578065 A JP 2021578065A JP 2022538894 A5 JP2022538894 A5 JP 2022538894A5
- Authority
- JP
- Japan
- Prior art keywords
- wild
- residue
- type human
- human neu2
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025197401A JP2026032063A (ja) | 2019-07-03 | 2025-11-18 | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962870403P | 2019-07-03 | 2019-07-03 | |
| US62/870,403 | 2019-07-03 | ||
| US202062957011P | 2020-01-03 | 2020-01-03 | |
| US62/957,011 | 2020-01-03 | ||
| PCT/US2020/040828 WO2021003469A2 (en) | 2019-07-03 | 2020-07-03 | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025197401A Division JP2026032063A (ja) | 2019-07-03 | 2025-11-18 | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538894A JP2022538894A (ja) | 2022-09-06 |
| JP2022538894A5 true JP2022538894A5 (https=) | 2023-07-10 |
| JP7777988B2 JP7777988B2 (ja) | 2025-12-01 |
Family
ID=74101301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578065A Active JP7777988B2 (ja) | 2019-07-03 | 2020-07-03 | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 |
| JP2025197401A Pending JP2026032063A (ja) | 2019-07-03 | 2025-11-18 | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025197401A Pending JP2026032063A (ja) | 2019-07-03 | 2025-11-18 | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220356457A1 (https=) |
| EP (1) | EP3994275A4 (https=) |
| JP (2) | JP7777988B2 (https=) |
| KR (1) | KR20220032576A (https=) |
| CN (1) | CN114258431A (https=) |
| AU (1) | AU2020301037A1 (https=) |
| BR (1) | BR112021026789A2 (https=) |
| CA (1) | CA3145676A1 (https=) |
| WO (1) | WO2021003469A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3735458A4 (en) | 2018-01-03 | 2022-04-27 | Palleon Pharmaceuticals Inc. | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF |
| CN114269937B (zh) * | 2019-07-03 | 2026-04-24 | 帕利昂制药有限公司 | 重组唾液酸酶及其使用方法 |
| AU2020299543A1 (en) * | 2019-07-03 | 2022-02-03 | Palleon Pharmaceuticals Inc. | Sialidase-HER2-antibody fusion proteins and methods of use thereof |
| CN114258431A (zh) * | 2019-07-03 | 2022-03-29 | 帕利昂制药有限公司 | 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法 |
| WO2025217138A1 (en) * | 2024-04-09 | 2025-10-16 | Palleon Pharmaceuticals Inc. | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same |
| WO2026037175A1 (zh) | 2024-08-16 | 2026-02-19 | 上海宝济药业股份有限公司 | 靶向靶细胞的复合物及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69415669T2 (de) * | 1993-05-17 | 1999-07-01 | Genentech, Inc., South San Francisco, Calif. | Sialidase defiziente zellen |
| US8512710B2 (en) * | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
| WO2007108464A1 (ja) | 2006-03-20 | 2007-09-27 | Kyowa Hakko Kogyo Co., Ltd. | 哺乳動物由来細胞質シアリダーゼに対する抗体 |
| CN100376689C (zh) * | 2006-03-28 | 2008-03-26 | 北京大学 | 一种预测达菲类药物用药安全性的方法 |
| EP2930245B1 (en) * | 2007-10-12 | 2017-11-22 | Sigma-Aldrich Co. LLC | Cell line and methods for improved glycoprotein sialylation |
| EP2711018A1 (en) * | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| AU2010315024B2 (en) * | 2009-11-06 | 2015-02-12 | Nexbio, Inc. | Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract |
| WO2014167112A1 (en) * | 2013-04-12 | 2014-10-16 | Danmarks Tekniske Universitet | A mutant sialidase having trans-sialidase activity for use in production of sialylated glycans |
| WO2018006066A1 (en) * | 2016-07-01 | 2018-01-04 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitory immune receptor inhibition methods and compositions |
| CN109641038A (zh) * | 2016-07-01 | 2019-04-16 | 小利兰·斯坦福大学理事会 | 靶向细胞表面编辑的共轭物 |
| CN111183220B (zh) | 2017-05-26 | 2024-03-22 | 杰诺维斯公司 | 用于聚糖分析的工具 |
| EP3735458A4 (en) * | 2018-01-03 | 2022-04-27 | Palleon Pharmaceuticals Inc. | RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF |
| US20250049846A1 (en) * | 2019-01-03 | 2025-02-13 | Palleon Pharmaceuticals Inc. | Methods and compositions for treating cancer with immune cells |
| CN114258431A (zh) * | 2019-07-03 | 2022-03-29 | 帕利昂制药有限公司 | 重组人唾液酸酶、唾液酸酶融合蛋白及其使用方法 |
-
2020
- 2020-07-03 CN CN202080058167.7A patent/CN114258431A/zh active Pending
- 2020-07-03 WO PCT/US2020/040828 patent/WO2021003469A2/en not_active Ceased
- 2020-07-03 BR BR112021026789A patent/BR112021026789A2/pt unknown
- 2020-07-03 JP JP2021578065A patent/JP7777988B2/ja active Active
- 2020-07-03 US US17/624,121 patent/US20220356457A1/en active Pending
- 2020-07-03 AU AU2020301037A patent/AU2020301037A1/en active Pending
- 2020-07-03 KR KR1020227003418A patent/KR20220032576A/ko active Pending
- 2020-07-03 CA CA3145676A patent/CA3145676A1/en active Pending
- 2020-07-03 EP EP20834151.1A patent/EP3994275A4/en active Pending
-
2025
- 2025-11-18 JP JP2025197401A patent/JP2026032063A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022538894A5 (https=) | ||
| JP2023532021A5 (https=) | ||
| JP7682150B2 (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| JP2023504914A5 (https=) | ||
| JP2024501771A5 (https=) | ||
| US20230174666A1 (en) | Anti-cd26 proteins and uses thereof | |
| RU2011138951A (ru) | Пропротеины и способы их применения | |
| SG193860A1 (en) | Fgf21 mutants and uses thereof | |
| US20240228586A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| WO2023186120A1 (zh) | 抗血清白蛋白纳米抗体及其衍生物 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| JP2023535695A5 (https=) | ||
| EP3944877A1 (en) | Nanobodies sars-cov2 | |
| KR20240035556A (ko) | 융합 폴리펩타이드를 이용하는 프로테아제 매개성의 표적 특이적 사이토카인 송달 | |
| CA3145676A1 (en) | Recombinant human sialidases, sialidase fusion proteins, and methods of using the same | |
| CN104292331B (zh) | 人源抗人α干扰素抗体及其应用 | |
| JP2024501767A5 (https=) | ||
| WO2021247675A1 (en) | Coronavirus-binding agents and uses thereof | |
| JP2023551194A5 (https=) | ||
| KR20200011685A (ko) | 갑상선 자극 호르몬 수용기(thyrotropin receptor, TSHR) 단편을 포함하는 융합 단백질 및 이의 용도 | |
| JP2024501770A5 (https=) | ||
| KR20210119421A (ko) | 탈면역화된 시가 독소 a 서브유닛 이펙터를 포함하는 cd38-결합 단백질(cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors) | |
| JP2024542235A5 (https=) | ||
| CA3218571A1 (en) | Methods of screening and expression of disulfide-bonded binding polypeptides | |
| US11401309B2 (en) | Protein M fusion proteins and uses |